Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 7/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 7/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 6/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 6/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 6/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5034714 | 0.95 | PDE2A (0.61) | PDE2AHDAC1HDAC6GABRA1GABRA5 | |
| SCHEMBL5038313 | 0.85 | PDE2A (0.56) | PDE2AHDAC1HDAC6GABRA1GABRA5 | |
| SCHEMBL5038249 | 0.84 | PDE2A (0.67) | PDE2AHDAC1HDAC6GABRA1GABRA5 | |
| SCHEMBL5038873 | 0.84 | PDE2A (0.60) | PDE2AHDAC1HDAC6GABRA1GABRA5 | |
| SCHEMBL5485199 | 0.83 | DDB1 (0.42) | PDE2AHDAC1HDAC6GABRA1GABRA5 | |
| SCHEMBL4410609 | 0.81 | PDE2A (0.44) | PDE2AHDAC1HDAC6GABRA1GABRA5 | |
| SCHEMBL5044357 | 0.81 | HDAC1 (0.58) | PDE2AHDAC1HDAC6GABRA1GABRA5 | |
| SCHEMBL4709463 | 0.80 | DDB1 (0.41) | PDE2AHDAC1HDAC6GABRA1GABRA5 | |
| SCHEMBL4709442 | 0.78 | HDAC1 (0.39) | PDE2AHDAC1HDAC6GABRA1GABRA5 | |
| SCHEMBL5038997 | 0.78 | PDE2A (0.66) | PDE2AHDAC1HDAC6GABRA1GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7410963-B2 | To treat diseases associated with abnormal regulation of intracellular cAMP and/or cGMP rate and abnormal regulation of neurotransmitter effect, with no perturbating effect on memory; autoinflammatory disorders; 3-(8-Methoxy-1-methyl-2-oxo-7-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)-benzonitrile | VIA PHARMACEUTICALS, INC. (US) | 2008-08-12 | — | — | US | claimed |
| US-20070123519-A1 | Benzo-1,4-diazepin-2-one derivatives as phosphodiesterase pde2 inhibitors, preparation and therapeutic use thereof | BAY CITY CAPITAL LLC | 2007-05-31 | — | — | US | claimed |
| US-7410963-B2 | To treat diseases associated with abnormal regulation of intracellular cAMP and/or cGMP rate and abnormal regulation of neurotransmitter effect, with no perturbating effect on memory; autoinflammatory disorders; 3-(8-Methoxy-1-methyl-2-oxo-7-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)-benzonitrile | VIA PHARMACEUTICALS, INC. (US) | 2008-08-12 | — | — | US | disclosed |
| US-20070123519-A1 | Benzo-1,4-diazepin-2-one derivatives as phosphodiesterase pde2 inhibitors, preparation and therapeutic use thereof | BAY CITY CAPITAL LLC | 2007-05-31 | — | — | US | disclosed |
| EP-1697332-A1 | BENZO'1,4 ! DIAZEPIN-2-ONE DERIVATIVES AS PHOSPHODIESTERASE PDE2 INHIBITORS, PREPARATION AND THERAPEUTIC USE THEREOF | NEURO3D (FR) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005063723-A1 | BENZO`1,4 ! DIAZEPIN-2-ONE DERIVATIVES AS PHOSPHODIESTERASE PDE2 INHIBITORS, PREPARATION AND THERAPEUTIC USE THEREOF | NEURO3D (FR) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123519-A1 | Benzo-1,4-diazepin-2-one derivatives as phosphodiesterase pde2 inhibitors, preparation and therapeutic use thereof | PDE12, PDE2A, PDE3A | PDE2A 2/4885HDAC1 147/4885HDAC6 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.